Webinar: Screening Tools for Population Health, Finding a Way to Help

From January 22, 2015 12:00 pm until January 22, 2015 1:00 pm Save to calendar

At Population Health Alliance 701 Pennsylvania Avenue Northwest #700, Washington, DC 20004, USA

Posted by Isabel Estrada

Listen to the Recording

If you are active in the stock market, you are likely familiar with stock screeners -- software tools that allow you to sort through the hundreds of thousands of stocks and mutual funds. These stock screeners are offered by all the top brands, Morningstar, Fidelity, eTrade, et al, and they help you identify stocks that meet a certain profile. These tools leverage technology and data to help you make decisions about where to invest.
This same capability is now becoming available in healthcare. It’s enabled by scientifically-derived predictive models, the latest electronic data capture technology, and a confluence of claim and clinical data, that until recently was considered closer to science fiction than reality.
The arrival of these new screening tools could not be better timed. The Agency of Healthcare Research and Quality found that just one percent of the population accounts for 21 percent of all health care spending in the United States. These are people with multiple conditions who often lack the knowledge or resources to seek out the care they need when they need it. As a result, they end up seeking care well after the onset of their medical condition, often ending up in the Emergency Room, which is the least efficient and most expensive option. They need our help. The challenge is to find them quickly and reach out to them proactively.
The implementation of the Affordable Care Act only makes this challenge more urgent. The removal of pre-existing condition clauses, the advent of Accountable Care Organizations, and performance-based reimbursement models all point to a seismic shift away from avoiding risk and toward managing it.
As policy makers and industry leaders, it is crucial that we get better at identifying these people and engaging them proactively to address their problems. At Optum, we are already developing and deploying these new screening tools. Tools that can help:

  • identify high risk individuals
  • screen for disease burden
  • predict future hospitalization
  • address medication non-adherence

And once these individuals are located, Optum offers best-in-class educational programs, health coaching and other resources to guide these folks to better care and helping to achieve the Triple Aim: better health for the population, better care for the individual and lower costs through improvements in the system.
We are just now beginning to see the impact these new screening tools can have. The work we are now doing with two regional health plans is already showing increased star ratings in key measures for medication adherence. And we are actively involved with a large health plan in California to better assess and screen dual eligible for more intensive outreach and care management.
These population health screening tools built on the latest electronic data capture platforms and fortified by predictive modeling algorithms will do for risk screening and care management programs what stock screeners have done to empower individual investors on the stock market.


GusGardnerGus Gardner, Group President, Patient Insights, Strategic Regulatory and Safety Services

Gus Gardner has over 21 years of senior management experience across several sectors of health care. As group president of the patient insights consultancy division of the Optum™ Life Sciences group, Gus is tasked with the day-to-day operations of Optum’s commercial business unit and chartered with translating the company’s visions and strategies into viable business tactics, effective operational processes and scalable methods.
His expertise includes the diagnosis and treatment of management and operational processes/systems in order to streamline communications and enhance efficiency. Gus also brings experience in integration management, mergers/acquisitions, sales channel development and new product introductions to his role. He joined Optum from Clinical Data, Inc., where he was first senior vice president and COO and then president of the company’s U.S. In-vitro Diagnostics division.
Prior to working at Clinical Data, Inc., Gus was president of POLESTAR Labs, a private company with clinical lab operations in 18 states. He has also served as vice president-western operations for Baxter Perfusion Services, Baxter International, Inc., where he managed cardiovascular services businesses with 500+ employees in 28 states. In addition, he was previously senior division president of PSICOR, Inc. (acquired by Baxter in 1994). Gus began his career as an officer in the United States Marine Corps.

Listen to the Recording

2015-01-22 12:00:00
2015-01-22 13:00:00